| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The application of BCH (1-100 mM; 3 days) to esophageal cancer cells (KYSE30 and KYSE150) exhibited dose-dependent inhibition of cell growth [1]. The number of G0/G1 phase cells in KYSE30 and KYSE150 cells was considerably enhanced by BCH (30 mM; 24 and 48 hours); this suggests that BCH induces cell cycle arrest in the G1 phase [1]. After 30 minutes, the phosphorylation of 4E-BP1 and p70S6K was reduced by BCH (30 mM; 0-24 h; KYSE30 and KYSE150 cells), and this reduction lasted for 24 hours. Protein levels of mTOR, 4E-BP1, and p70S6K are marginally decreased [1].
|
|---|---|
| ln Vivo |
The treatment of male BALB/c nude mice with BCH (200 mg/kg; intravenous injection; daily; for 14 days) significantly delayed the growth of the tumor and decreased glucose metabolism, indicating that LAT1 inhibition may prevent the growth of esophageal cancer in vivo [1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: KYSE30 and KYSE150 Esophageal cancer cells Tested Concentrations: 1 mM, 3 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM or 100 mM Incubation Duration: 3 days Experimental Results: Cell proliferation was inhibited in a dose-dependent manner. Cell cycle analysis[1] Cell Types: KYSE30 and KYSE150 Cell Tested Concentrations: 30 mM Incubation Duration: 24 and 48 hrs (hours) Experimental Results: Cell cycle arrest. Western Blot Analysis [1] Cell Types: KYSE30 and KYSE150 Cell Tested Concentrations: 30 mM Incubation Duration: 0 hrs (hours), 0.5 hrs (hours), 1 hour, 3 hrs (hours), 6 hrs (hours), 24 hrs (hours) Experimental Results: diminished phosphorylation of 4E-BP1 and p70S6K. The amounts of mTOR, 4E-BP1 and p70S6K proteins were slightly diminished. |
| Animal Protocol |
Animal/Disease Models: Male BALB/c nude mice (5 weeks old) KYSE150 cells [1]
Doses: 200 mg/kg Route of Administration: intravenous (iv) (iv)injection; daily; continued for 14 days Experimental Results: Dramatically delayed tumor growth and diminished glucose metabolism. |
| References |
|
| Additional Infomation |
2-Amino-2-norbornanecarboxylic acid is a monoterpenoid.
|
| Molecular Formula |
C8H13NO2
|
|---|---|
| Molecular Weight |
155.19432
|
| Exact Mass |
155.095
|
| CAS # |
20448-79-7
|
| PubChem CID |
115288
|
| Appearance |
White to off-white solid powder
|
| Density |
1.256g/cm3
|
| Boiling Point |
295.5ºC at 760 mmHg
|
| Melting Point |
>300 °C(lit.)
|
| Flash Point |
132.5ºC
|
| Vapour Pressure |
0.000369mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
1.288
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
204
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MPUVBVXDFRDIPT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H13NO2/c9-8(7(10)11)4-5-1-2-6(8)3-5/h5-6H,1-4,9H2,(H,10,11)
|
| Chemical Name |
2-aminobicyclo[2.2.1]heptane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~20 mg/mL (~128.87 mM)
DMSO : ~1 mg/mL (~6.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 12.5 mg/mL (80.55 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4437 mL | 32.2186 mL | 64.4371 mL | |
| 5 mM | 1.2887 mL | 6.4437 mL | 12.8874 mL | |
| 10 mM | 0.6444 mL | 3.2219 mL | 6.4437 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
